Visual function in human ocular toxoplasmosis

British Journal of Ophthalmology

Volumn 91, Issue 2, 2007, Pages 233-236

  Scherrer, Janine ^b   Iliev, Milko E ^b   Halberstadt, Markus ^c   Kodjikian, Laurent ^d   Garweg, Justus G ^a  

^a Swiss Eye Institute   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLINDNESS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; PERIMETRY; PREVALENCE; PRIORITY JOURNAL; TOXOPLASMOSIS; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIMETRY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TOXOPLASMOSIS, OCULAR; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 33846840990     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.100925     Document Type: Article

References (32)

1. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: Epidemiology and course of disease. Am J Ophthalmol 2003;136:973- 88.
2. Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis. Japan J Ophthalmol 2004;48:386-91.
3. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, et al. Ocular toxoplasmosis: clinical features and prognosis in 154 patients. Ophthalmology 2002;109:869-78.
4. Mets MB, Holfels E, Boyer KM, et al. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol 1996;122:309-24.
5. Friedmann CT, Knox D. Variations in recurrent active toxoplasmic retinochoroiditis. Arch Ophthalmol 1969;81:481-93.
6. Kadarisman RS, Marsetio M, Simangunsong LB. Visual impairment and blindness in ocular toxoplasmosis cases. Southeast Asian J Trop Med Public Health 1991;22(Suppl):99-101.
7. Brezin AP, Thulliez P, Couvreur J, et al. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol 2003;135:779-84.
8. De Carvalho KM, Minguini N, Moreira Filho DC, et al. Characteristics of a pediatric low-vision population. J Pediatr Ophthalmol Strabismus 1998;35:162-5.
9. Saari M. Toxoplasmic chorioretinitis affecting the macula. Acta Ophthalmol 1977;55:539-47.
10. Suhardjo, Utomo PT, Agni AN. Clinical manifestations of ocular toxoplasmosis in Yogyakarta, Indonesia: a clinical review of 173 cases. Southeast Asian J Trop Med Public Health 2003;34:291-7.
11. O'Neill JF. The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis. Trans Am Ophthalmol Soc 1998;96:813-79.
12. Mattews JD, Weiter JJ. Outer retinal toxoplasmosis. Ophthalmology 1988;95:941-6.
13. Weiter JJ, Wing GL, Trempe CL, et al. Visual acuity related to retinal distance from the fovea in macular disease. Ann Ophthalmol 1984;16:174-6.
14. Banta JT, Davis JL, Lam BL. Presumed toxoplasmosic anterior optic neuropathy. Ocul Immunol Inflamm 2002;10:201-11.
15. Pian D, Ferrucci S, Anderson SF, et al. Paramacular coloboma. Optom Vis Sci 2003;80:556-63.
16. Wilder HC. Toxoplasma chorioretinitis in adults. Arch Ophthalmol 1952;48:127-36.
17. Martin WG, Brown GC, Parrish RK, et al. Ocular toxoplasmosis and visual field defects. Am J Ophthalmol 1980;90:25-9.
18. Enoch JM, Essock EA, Willilams RA, et al. Functional visual effects of lesions located near the optic nerve head. Doc Ophthalmol 1985;61:137-56.
19. Janknecht P, Soriano JM, Funk J, et al. Automatische Perimetrie des zentralen Gesichtfeldes bei Erkrankungen der Makula. Klin Monatsbl Augenheilkd 1991;199:259-63.
20. Wenkel H, Schönherr U. Retinochoroiditis als diagnostischer Hinweis auf eine akute systemische Toxoplasmose bei einem immunkompetenten Patienten. Klin Monatsbl Augenheilkd 1995;207:314-15.
21. Stanford MR, Tomlin EA, Comyn O. The visual field in ocular toxoplasmosis. Br J Ophthalmol 2005;89:812-14.
22. Gilbert HD. Unusual presentation of acute ocular toxoplasmosis. Graefe's Arch Clin Exp Ophthalmol 1980;215:53-8.
23. Schlaegel Jr TF, Weber JC. The macula in ocular toxoplasmosis. Arch Ophthalmol 1984;102:697-8.
24. Weijland A, Fankhauser F, Bebie H, et al. Automated perimetry. Visual field digest, 5th edn. Haag-Streit, Koeniz, Switzerland 2004: 60-62, 92-106.
25. Jaakkola A, Vesti E, Immonen I. Correlation between Octopus perimetry and fluorescein angiography after Strontium-90 plaque brachytherapy for subfoveal exudative age related macular degeneration. Br J Ophthalmol 1998;82:763-8.
26. World Health Organization, WHO Media Centre. Magnitude and causes of visual impairment. http://www.who.int/mediacentre/factsheets/fs282/en/index. html.
27. Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: Disease manifestations and management. Am J Ophthalmol 2004;137:1-17.
28. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004;113:1567-72.
29. Sirveira C, Belfort Jr R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 2002;134:41-6.
30. Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005;112:1876-82.
31. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 2002;134:102- 14.
32. Eckert GU, Melamed J, Menegaz B. Optic nerve changes in ocular toxoplasmosis. Eye Epub 31 Mar, 2006.